{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:44:40Z","timestamp":1769723080789,"version":"3.49.0"},"reference-count":57,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Buprenorphine is underutilized as a treatment for opioid use disorder (OUD); state policies may improve buprenorphine access and utilization.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess buprenorphine prescribing trends following New Jersey Medicaid initiatives designed to improve access.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional interrupted time series analysis included New Jersey Medicaid beneficiaries who were prescribed buprenorphine and had 12 months continuous Medicaid enrollment, OUD diagnosis, and no Medicare dual eligibility, as well as physician or advanced practitioners who prescribed buprenorphine to Medicaid beneficiaries. The study used Medicaid claims data from 2017 to 2021.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Implementation of New Jersey Medicaid initiatives in 2019 that removed prior authorizations, increased reimbursement for office-based OUD treatment, and established regional Centers of Excellence.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Rate of buprenorphine receipt per 1000 beneficiaries with OUD; percentage of new buprenorphine episodes lasting at least 180 days; buprenorphine prescribing rate per 1000 Medicaid prescribers, overall and by specialty.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 101\u202f423 Medicaid beneficiaries (mean [SD] age, 41.0 [11.6] years; 54\u202f726 [54.0%] male; 30\u202f071 [29.6%] Black, 10\u202f143 [10.0%] Hispanic, and 51\u202f238 [50.5%] White), 20\u202f090 filled at least 1 prescription for buprenorphine from 1788 prescribers. Policy implementation was associated with an inflection point in buprenorphine prescribing trend; after implementation, the trend increased by 36%, from 1.29 (95% CI, 1.02-1.56) prescriptions per 1000 beneficiaries with OUD to 1.76 (95% CI, 1.46-2.06) prescriptions per 1000 beneficiaries with OUD. Among beneficiaries with new buprenorphine episodes, the percentage retained for at least 180 days was stable before and after initiatives were implemented. The initiatives were associated with an increase in the growth rate of buprenorphine prescribers (0.43 per 1000 prescribers; 95% CI, 0.34 to 0.51 per 1000 prescribers). Trends were similar across specialties, but increases were most pronounced among primary care and emergency medicine physicians (eg, primary care: 0.42 per 1000 prescribers; 95% CI, 0.32-0.53 per 1000 prescribers). Advanced practitioners accounted for a growing percentage of buprenorphine prescribers, with a monthly increase of 0.42 per 1000 prescribers (95% CI, 0.32-0.52 per 1000 prescribers). A secondary analysis to test for changes associated with non\u2013state-specific secular trends in prescribing found that quarterly trends in buprenorphine prescriptions increased in New Jersey relative to all other states following initiative implementation.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cross-sectional study of state-level New Jersey Medicaid initiatives designed to expand buprenorphine access, implementation was associated with an upward trend in buprenorphine prescribing and receipt. No change was observed in the percentage of new buprenorphine treatment episodes lasting 180 or more days, indicating that retention remains a challenge. Findings support implementation of similar initiatives but highlight the need for efforts to support long-term retention.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.12030","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T15:30:58Z","timestamp":1683300658000},"page":"e2312030","source":"Crossref","is-referenced-by-count":11,"title":["Buprenorphine Utilization and Prescribing Among New Jersey Medicaid Beneficiaries After Adoption of Initiatives Designed to Improve Treatment Access"],"prefix":"10.1001","volume":"6","author":[{"given":"Peter","family":"Treitler","sequence":"first","affiliation":[{"name":"Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey"},{"name":"School of Social Work, Rutgers University, New Brunswick, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Nowels","sequence":"additional","affiliation":[{"name":"Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey"},{"name":"School of Public Health, Rutgers University, Piscataway, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillary","family":"Samples","sequence":"additional","affiliation":[{"name":"Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey"},{"name":"School of Public Health, Rutgers University, Piscataway, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Crystal","sequence":"additional","affiliation":[{"name":"Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey"},{"name":"School of Social Work, Rutgers University, New Brunswick, New Jersey"},{"name":"School of Public Health, Rutgers University, Piscataway, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"issue":"3","key":"zoi230374r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3821","article-title":"Use of medication for opioid use disorder among us adolescents and adults with need for opioid treatment, 2019.","volume":"5","author":"Mauro","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi230374r4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1001\/jama.2021.7374","article-title":"Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 states, 2014-2018.","volume":"326","author":"Donohue","year":"2021","journal-title":"JAMA"},{"key":"zoi230374r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108513","article-title":"Medicaid participation among practitioners authorized to prescribe buprenorphine.","volume":"133","author":"Saunders","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"zoi230374r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108083","article-title":"Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study.","volume":"213","author":"Roehler","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"21","key":"zoi230374r7","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1001\/jama.2021.4469","article-title":"Concentration of patient care among buprenorphine-prescribing clinicians in the US.","volume":"325","author":"Stein","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"zoi230374r8","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1377\/hlthaff.2019.01622","article-title":"Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists, and others.","volume":"39","author":"Olfson","year":"2020","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"zoi230374r9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3122\/jabfm.2020.01.190233","article-title":"Characteristics of office-based buprenorphine prescribers for Medicare patients.","volume":"33","author":"Abraham","year":"2020","journal-title":"J Am Board Fam Med"},{"issue":"3","key":"zoi230374r10","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","article-title":"Barriers and facilitators to the use of medications for opioid use disorder: a rapid review.","volume":"35","author":"Mackey","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"2","key":"zoi230374r11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11414-021-09783-z","article-title":"To prescribe or not to prescribe? barriers and motivators for progressing along each stage of the buprenorphine training and prescribing path.","volume":"50","author":"Winograd","year":"2023","journal-title":"J Behav Health Serv Res"},{"key":"zoi230374r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108811","article-title":"Primary care physicians\u2019 preparedness to treat opioid use disorder in the United States: A cross-sectional survey.","volume":"225","author":"Foti","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"zoi230374r13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamapsychiatry.2018.3685","article-title":"Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver.","volume":"76","author":"Fiscella","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"zoi230374r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.12419","article-title":"Survey of barriers and facilitators to prescribing buprenorphine and clinician perceptions on the Drug Addiction Treatment Act of 2000 waiver.","volume":"5","author":"Lanham","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi230374r15","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1377\/hlthaff.2012.0294","article-title":"In 2011 nearly one-third of physicians said they would not accept new Medicaid patients, but rising fees may help.","volume":"31","author":"Decker","year":"2012","journal-title":"Health Aff (Millwood)"},{"issue":"9","key":"zoi230374r16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamapsychiatry.2019.0958","article-title":"Medicaid acceptance by psychiatrists before and after Medicaid expansion.","volume":"76","author":"Wen","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"zoi230374r19","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.4001","article-title":"Coverage and prior authorization policies for medications for opioid use disorder in Medicaid managed care.","volume":"3","author":"Abraham","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"5","key":"zoi230374r28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.9463","article-title":"Changes in US Medicaid enrollment during the COVID-19 pandemic.","volume":"4","author":"Khorrami","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi230374r29","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7832752","article-title":"Factors influencing buprenorphine prescribing among physicians in New York State.","volume":"2019","author":"Marino","year":"2019","journal-title":"J Addict"},{"key":"zoi230374r30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugpo.2017.11.021","article-title":"A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.","volume":"54","author":"Andraka-Christou","year":"2018","journal-title":"Int J Drug Policy"},{"issue":"4","key":"zoi230374r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3132","article-title":"Association of formulary prior authorization policies with buprenorphine-naloxone prescriptions and hospital and emergency department use among Medicare beneficiaries.","volume":"3","author":"Mark","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi230374r32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2105\/AJPH.2018.304856","article-title":"Impact of Medicaid restrictions on availability of buprenorphine in addiction treatment programs.","volume":"109","author":"Andrews","year":"2019","journal-title":"Am J Public Health"},{"issue":"6","key":"zoi230374r34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1177\/10775587221086489","article-title":"State policies and buprenorphine prescribing by nurse practitioners and physician assistants.","volume":"79","author":"Harrison","year":"2022","journal-title":"Med Care Res Rev"},{"issue":"2","key":"zoi230374r35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2105\/AJPH.2020.306000","article-title":"Increasing access to buprenorphine in safety-net primary care clinics: the New York City Buprenorphine Nurse Care Manager Initiative.","volume":"111","author":"Kaplan-Dobbs","year":"2021","journal-title":"Am J Public Health"},{"issue":"1","key":"zoi230374r36","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/08897077.2021.1931633","article-title":"Project ECHO and primary care buprenorphine treatment for opioid use disorder: implementation and clinical outcomes.","volume":"43","author":"Anderson","year":"2022","journal-title":"Subst Abus"},{"issue":"1","key":"zoi230374r37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13722-021-00215-z","article-title":"The impact of project ECHO on physician preparedness to treat opioid use disorder: a systematic review.","volume":"16","author":"Puckett","year":"2021","journal-title":"Addict Sci Clin Pract"},{"issue":"6","key":"zoi230374r38","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.1757","article-title":"Buprenorphine use trends following removal of prior authorization policies for the treatment of opioid use disorder in 2 state Medicaid programs.","volume":"3","author":"Keshwani","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"6","key":"zoi230374r39","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.0189","article-title":"The consequences of removing prior authorization for buprenorphine in Medicaid\u2014building an evidence base.","volume":"3","author":"Allen","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"9","key":"zoi230374r40","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.ajem.2019.02.025","article-title":"Barriers and facilitators for emergency department initiation of buprenorphine: a physician survey.","volume":"37","author":"Lowenstein","year":"2019","journal-title":"Am J Emerg Med"},{"issue":"4","key":"zoi230374r41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/15563650.2020.1805461","article-title":"Physician attitudes on buprenorphine induction in the emergency department: results from a multistate survey.","volume":"59","author":"Zuckerman","year":"2021","journal-title":"Clin Toxicol (Phila)"},{"issue":"3","key":"zoi230374r42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.annemergmed.2018.08.439","article-title":"A quality framework for emergency department treatment of opioid use disorder.","volume":"73","author":"Samuels","year":"2019","journal-title":"Ann Emerg Med"},{"issue":"5","key":"zoi230374r43","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.5811\/westjem","article-title":"Emergency department visits by patients with substance use disorder in the United States.","volume":"22","author":"Zhang","year":"2021","journal-title":"West J Emerg Med"},{"issue":"4","key":"zoi230374r44","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.annemergmed.2018.04.007","article-title":"Identification, management, and transition of care for patients with opioid use disorder in the emergency department.","volume":"72","author":"Duber","year":"2018","journal-title":"Ann Emerg Med"},{"issue":"12","key":"zoi230374r46","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1377\/hlthaff.2019.00859","article-title":"In rural areas, buprenorphine waiver adoption since 2017 driven by nurse practitioners and physician assistants.","volume":"38","author":"Barnett","year":"2019","journal-title":"Health Aff (Millwood)"},{"key":"zoi230374r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108715","article-title":"Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing.","volume":"138","author":"Andraka-Christou","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"zoi230374r48","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/10775587211004311","article-title":"The association between scope of practice regulations and nurse practitioner prescribing of buprenorphine after the 2016 Opioid Bill.","volume":"79","author":"Nguyen","year":"2022","journal-title":"Med Care Res Rev"},{"key":"zoi230374r49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108514","article-title":"Perspectives of opioid use disorder treatment providers during COVID-19: adapting to flexibilities and sustaining reforms.","volume":"132","author":"Treitler","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"zoi230374r50","doi-asserted-by":"publisher","DOI":"10.1146\/knowable-042922-1","article-title":"Does online opioid treatment work?","author":"Butcher","year":"2022","journal-title":"Knowable Mag"},{"issue":"2","key":"zoi230374r51","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder.","volume":"177","author":"Williams","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"5","key":"zoi230374r52","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid.","volume":"39","author":"Samples","year":"2020","journal-title":"Health Aff (Millwood)"},{"key":"zoi230374r53","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109269","article-title":"Opioid overdose survivors: Medications for opioid use disorder and risk of repeat overdose in Medicaid patients.","volume":"232","author":"Crystal","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"zoi230374r54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108446","article-title":"Buprenorphine utilization among all Washington State residents\u2019 based upon prescription monitoring program data\u2014characteristics associated with two measures of retention and patterns of care over time.","volume":"127","author":"Banta-Green","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"zoi230374r55","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis.","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"zoi230374r56","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"zoi230374r2","year":"2019"},{"key":"zoi230374r1","unstructured":"The White House. National Drug Control Strategy. Accessed March 20, 2023. https:\/\/www.whitehouse.gov\/ondcp\/national-drug-control-strategy"},{"key":"zoi230374r17","unstructured":"Orgera? K, Tolbert? J. The opioid epidemic and Medicaid\u2019s role in facilitating access to treatment. Kaiser Family Foundation. May 24, 2019. Accessed March 20, 2023. https:\/\/www.kff.org\/medicaid\/issue-brief\/the-opioid-epidemic-and-medicaids-role-in-facilitating-access-to-treatment"},{"key":"zoi230374r18","unstructured":"State of New Jersey, Department of Human Services, Division of Medical Assistance & Health Services. Newsletter: office based addictions treatment (OBAT) and elimination of prior authorization for medication assisted treatment (MAT) for all MAT providers. November 2019. Accessed March 20, 2023. https:\/\/www.njmmis.com\/downloadDocuments\/29-18.pdf"},{"key":"zoi230374r20","unstructured":"State of New Jersey, Department of Human Services, Division of Medical Assistance & Health Services. Newsletter: Office Based Addiction Treatment (OBAT) update\u2014enrollment of OBAT navigators as servicing providers. March 2020. Accessed March 20, 2023. https:\/\/www.njmmis.com\/downloadDocuments\/30-03.pdf"},{"key":"zoi230374r21","unstructured":"Northern New Jersey MAT Center of Excellence. Accessed March 20, 2023. https:\/\/sites.rutgers.edu\/mat-coe"},{"key":"zoi230374r22","unstructured":"Southern New Jersey MAT Center of Excellence. Accessed March 20, 2023. https:\/\/www.snjmatcoe.org"},{"key":"zoi230374r23","unstructured":"Tunney? S; NJ Department of Human Services, Division of Medical Assistance and Health Services. NJ MATrx Model. January 16, 2019. Accessed March 20, 2023. https:\/\/www.nj.gov\/humanservices\/dmhas\/information\/provider\/Provider_Meetings\/2019\/MAAC%20OBAT.pdf"},{"key":"zoi230374r24","unstructured":"US Centers for Medicare & Medicaid Services. NPPES NPI Registry. Accessed March 20, 2023. https:\/\/npiregistry.cms.hhs.gov"},{"key":"zoi230374r25","unstructured":"National Uniform Claim Committee. Health care provider taxonomy. Accessed March 20, 2023. https:\/\/www.nucc.org\/index.php\/code-sets-mainmenu-41\/provider-taxonomy-mainmenu-40"},{"key":"zoi230374r26","unstructured":"Hyndman? R. Package \u2018forecast.\u2019 February 27, 2023. Accessed March 20, 2023. https:\/\/cran.r-project.org\/web\/packages\/forecast\/forecast.pdf"},{"key":"zoi230374r27","unstructured":"Centers for Medicare & Medicaid Services. State drug utilization data. December 19, 2022. Accessed March 20, 2023. https:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/state-drug-utilization-data\/index.html"},{"key":"zoi230374r33","unstructured":"Cunningham? P, Pierre-Louis? S, Britton? E, Farzana Urmi? A, Barnes? A. Addiction and Recovery Treatment Services: evaluation report for state fiscal years 2019 and 2020. Virginia Commonwealth University, School of Medicine. 2022. Accessed March 28, 2023. https:\/\/hbp.vcu.edu\/media\/hbp\/policybriefs\/pdfs\/ARTSYear4ComprehensiveReport.5.4.22.pdf"},{"key":"zoi230374r45","unstructured":"SUPPORT for Patients and Communities Act, HR 6, 115th Congress (2017-2018). Accessed March 20, 2023. https:\/\/www.congress.gov\/bill\/115th-congress\/house-bill\/6"},{"key":"zoi230374r57","unstructured":"Sugar? S, Peters? C, De Lew? N, Sommers? BD. Medicaid churning and continuity of care: evidence and policy considerations before and after the COVID-19 pandemic (Issue Brief No. HP-2021-10). Office of the Assistant Secretary for Planning and Evaluation, US Department of Health and Human Services. April 21, 2021. Accessed March 20, 2023. https:\/\/aspe.hhs.gov\/sites\/default\/files\/private\/pdf\/265366\/medicaid-churning-ib.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2804553\/treitler_2023_oi_230374_1682627018.8333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T15:31:04Z","timestamp":1683300664000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2804553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.12030","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]}}}